Literature DB >> 8644702

Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

O Johannsson1, E A Ostermeyer, S Håkansson, L S Friedman, U Johansson, G Sellberg, K Brøndum-Nielsen, V Sele, H Olsson, M C King, A Borg.   

Abstract

Nine different germ-line mutations in the BRCA1 breast and ovarian cancer susceptibility gene were identified in 15 of 47 kindreds from southern Sweden, by use of SSCP and heteroduplex analysis of all exons and flanking intron region and by a protein-truncation test for exon 11, followed by direct sequencing. All but one of the mutations are predicted to give rise to premature translation termination and include seven frameshift insertions or deletions, a nonsense mutation, and a splice acceptor site mutation. The remaining mutation is a missense mutation (Cys61Gly) in the zinc-binding motif. Four novel Swedish founding mutations were identified: the nucleotide 2595 deletion A was found in five families, the C 1806 T nonsense mutation in three families, the 3166 insertion TGAGA in three families, and the nucleotide 1201 deletion 11 in two families. Analysis of the intragenic polymorphism D17S855 supports common origins of the mutations. Eleven of the 15 kindreds manifesting BRCA1 mutations were breast-ovarian cancer families, several of them with a predominant ovarian cancer phenotype. The set of 32 families in which no BRCA1 alterations were detected included 1 breast-ovarian cancer kindred manifesting clear linkage to the BRCA1 region and loss of the wild-type chromosome in associated tumors. Other tumor types found in BRCA1 mutation/haplotype carriers included prostatic, pancreas, skin, and lung cancer, a malignant melanoma, an oligodendroglioma, and a carcinosarcoma. In all, 12 of 16 kindreds manifesting BRCA1 mutation or linkage contained ovarian cancer, as compared with only 6 of the remaining 31 families (P<.001). The present study confirms the involvement of BRCA1 in disease predisposition for a subset of hereditary breast cancer families often characterized by ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644702      PMCID: PMC1914564     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  27 in total

1.  The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers.

Authors:  H Aberle; C Bierkamp; D Torchard; O Serova; T Wagner; E Natt; J Wirsching; C Heidkämper; M Montagna; H T Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

2.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.

Authors:  M E Thompson; R A Jensen; P S Obermiller; D L Page; J T Holt
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

3.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

Authors:  R Wooster; S L Neuhausen; J Mangion; Y Quirk; D Ford; N Collins; K Nguyen; S Seal; T Tran; D Averill
Journal:  Science       Date:  1994-09-30       Impact factor: 47.728

4.  Regulation of BRCA1.

Authors:  M A Brown; H Nicolai; C F Xu; B L Griffiths; K A Jones; E Solomon; L Hosking; J Trowsdale; D M Black; R McFarlane
Journal:  Nature       Date:  1994 Dec 22-29       Impact factor: 49.962

5.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

6.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

7.  BRCA1 mutations in primary breast and ovarian carcinomas.

Authors:  P A Futreal; Q Liu; D Shattuck-Eidens; C Cochran; K Harshman; S Tavtigian; L M Bennett; A Haugen-Strano; J Swensen; Y Miki
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

8.  Clinical/genetic features in hereditary breast cancer.

Authors:  H T Lynch; P Watson; T A Conway; J F Lynch
Journal:  Breast Cancer Res Treat       Date:  1990-02       Impact factor: 4.872

9.  Rapid detection of BRCA1 mutations by the protein truncation test.

Authors:  F B Hogervorst; R S Cornelis; M Bout; M van Vliet; J C Oosterwijk; R Olmer; B Bakker; J G Klijn; H F Vasen; H Meijers-Heijboer
Journal:  Nat Genet       Date:  1995-06       Impact factor: 38.330

10.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

View more
  38 in total

1.  BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.

Authors:  Danièle Muller; Catherine Bonaiti-Pellié; Joseph Abecassis; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

2.  Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; P Arlauskas; W Du; V K Vaitkevicius; J D Crissman; F H Sarkar
Journal:  Int J Pancreatol       Date:  1997-06

3.  Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.

Authors:  Zakaria Einbeigi; Annika Bergman; Jeanne M Meis-Kindblom; Anna Flodin; Cecilia Bjursell; Tommy Martinsson; Lars-Gunnar Kindblom; Jan Wahlström; Arne Wallgren; Margareta Nordling; Per Karlsson
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

4.  Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?

Authors:  O M Serova; S Mazoyer; N Puget; V Dubois; P Tonin; Y Y Shugart; D Goldgar; S A Narod; H T Lynch; G M Lenoir
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

5.  BRCA1 mutation update and analysis.

Authors:  K Grade; B Jandrig; S Scherneck
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Population genetics of BRCA1 and BRCA2.

Authors:  C I Szabo; M C King
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

7.  Association between CLPTM1L polymorphisms (rs402710 and rs401681) and lung cancer susceptibility: evidence from 27 case-control studies.

Authors:  De-ping Zhao; Chen-lu Yang; Xiao Zhou; Jia-an Ding; Ge-ning Jiang
Journal:  Mol Genet Genomics       Date:  2014-06-07       Impact factor: 3.291

8.  Mutation analysis of BRCA1 gene in African-American patients with breast cancer.

Authors:  D Shen; Y Wu; M Subbarao; H Bhat; R Chillar; J V Vadgama
Journal:  J Natl Med Assoc       Date:  2000-01       Impact factor: 1.798

9.  Detection of false positive mutations in BRCA gene by next generation sequencing.

Authors:  Moushumi Suryavanshi; Dushyant Kumar; Manoj Kumar Panigrahi; Meenakshi Chowdhary; Anurag Mehta
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

10.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Authors:  P N Tonin; A M Mes-Masson; P A Futreal; K Morgan; M Mahon; W D Foulkes; D E Cole; D Provencher; P Ghadirian; S A Narod
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.